CYP3A4*18 AND CYP3A5*3 GENE POLYMORPHISMS AND IMATINIB RESISTANCE IN MALAYSIAN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA

被引：2
|
作者：
Ankathil, R. [1 ]
Zian, A. A. [1 ]
Nizam, Z. M. [1 ]
Azlan, H. [1 ]
Baba, A. A. [2 ]
机构：
[1] Univ Sains Malaysia, Ctr Human Genome, Kota Baharu, Kelantan, Malaysia
[2] Int Med Univ, Kuala Lumpur 57000, Malaysia
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/j.ejca.2014.03.267
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P0223
引用
收藏
页码：E71 / E72
页数：2
相关论文
共 50 条
  • [31] Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population
    Salameh, Ghada
    Al Hadidi, Kamal
    El Khateeb, Mohammad
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2012, 34 (01) : 23 - 33
  • [32] Influence of CYP3A4*22 and CYP3A5*3 genetic polymorphisms on tacrolimus pharmacokinetics in adult renal transplant patients
    Salvador, Pilar
    Outeda, Maria
    Pedreira, Isaura
    Fernandez, Constantino
    Alonso, Angel
    Martin, Isabel
    TRANSPLANTATION, 2016, 100 (07) : S709 - S709
  • [33] Effect of CYP3A5 genotype on the relationship between hepatic CYP3A activity and CYP3A4 and CYP3A5 mRNA expression
    Kolwankar, D
    Ho, H
    Ethell, B
    Vuppalanchi, R
    Marri, SR
    Wrighton, SA
    Jones, DR
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [34] Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant
    Hannachi, Ibtissem
    Ben Fredj, Nadia
    Chadli, Zohra
    Ben Fadhel, Najah
    Ben Romdhane, Haifa
    Touitou, Yvan
    Boughattas, Naceur A.
    Chaabane, Amel
    Aouam, Karim
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 396
  • [35] USE OF THE CYP3A4 SELECTIVE INHIBITOR CYP3CIDE IN CYP3A5 GENOTYPED CRYOPRESERVED HUMAN HEPATOCYTES TO EXPLORE THE INDIVIDUAL CONTRIBUTION OF CYP3A4 AND CYP3A5 IN DRUG METABOLISM
    Heyward, Scott
    Schultz, Rachel N. V.
    Dennell, Stephen
    DRUG METABOLISM REVIEWS, 2014, 45 : 135 - 136
  • [36] Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy
    Coto, Eliecer
    Tavira, Beatriz
    Marin, Rafael
    Ortega, Francisco
    Lopez-Larrea, Carlos
    Ruiz-Ortega, Marta
    Ortiz, Alberto
    Diaz, Marta
    Corao, Ana I.
    Alonso, Belen
    Alvarez, Victoria
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 397 (03) : 576 - 579
  • [37] Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers
    Zhang, Jing
    Dai, Ying
    Liu, Zhihong
    Zhang, Minxin
    Li, Chen
    Chen, Dingxiong
    Song, Hongtao
    THERAPEUTIC DRUG MONITORING, 2017, 39 (04) : 406 - 411
  • [38] The genotype-phenotype association of CYP3A4 and CYP3A5 polymorphisms to midazolam clearance in vivo
    He, P
    Court, MH
    Greenblatt, DJ
    von Moltke, LL
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1209 - 1209
  • [39] The genotype-phenotype association of CYP3A4 and CYP3A5 polymorphisms to midazolam hydroxylation in vivo
    He, P
    Court, MH
    Greenblatt, DJ
    von Moltke, LL
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [40] Evaluating the Effect of CYP3A4 and CYP3A5 Polymorphisms on Cyclosporine, Everolimus and Tacrolimus Pharmacokinetics in Renal Transplantation Patients
    Moes, D. J. A. R.
    Swen, J. J.
    den Hartigh, J.
    van der Straaten, T.
    van der Heide, Homan J. J.
    Bemelman, F.
    de Fijter, J. W.
    Guchelaar, H. J.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 672 - 672
12345